Drugs Made In America Acquisition Corp.
DMAA
$10.33
$0.000.00%
NASDAQ
| 09/30/2025 | 06/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 99.92% | -60.14% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 99.92% | -60.14% | |||
| Operating Income | -99.92% | 60.14% | |||
| Income Before Tax | -4.54% | 82.43% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -4.54% | 82.43% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -4.54% | 82.43% | |||
| EBIT | -99.92% | 60.14% | |||
| EBITDA | -- | -- | |||
| EPS Basic | -4.54% | 34.98% | |||
| Normalized Basic EPS | -4.68% | 35.13% | |||
| EPS Diluted | -4.54% | 38.82% | |||
| Normalized Diluted EPS | -4.68% | 39.09% | |||
| Average Basic Shares Outstanding | 0.00% | 35.20% | |||
| Average Diluted Shares Outstanding | 0.00% | 31.40% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||